Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Importance Intravenous magnesium sulfate administered to pregnant individuals before birth
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

There is an important unmet need to improve long term outcomes of encephalopathy for
preterm and term infants. Meta-analyses of large controlled trials suggest that maternal …

Prematurity remains a proximate cause of infant morbidity and mortality. 1 Despite extensive
years of research and investment, limited gains have been made in preventing preterm birth …

Improving neurodevelopmental outcome for preterm infants is an important challenge for
neonatal medicine. The disruption of normal brain growth and neurological development is …

The neuro-protective effect of antenatal magnesium sulfate on very preterm infants has been
demonstrated in good-quality randomised controlled trials and meta-analyses. Magnesium …

Introduction: Clinical trial designs based on the assumption of independent observations are
well established. Clustered clinical trial designs, where all observational units belong to a …